PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Key Points Question Does adding PDS0101 to pembrolizumab demonstrate antitumor activity and tolerability in patients with recurrent/metastatic human papillomavirus type 16–positive head and neck squamous cell carcinoma who are immune checkpoint inhibitor (ICI)–naive or ICI-resistant? Findings In this nonrandomized clin...